References
[1] Li, X., et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer, 2021, 21(9): p. 541-557.
[2] Anwanwan, D., et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer, 2020. 1873(1): p. 188314.
[3] Llovet, J.M., et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 2021. 7(1): p. 6.
[4] Yu, L.X. and R.F. Schwabe. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol, 2017, 14(9): p. 527-539.
[5] Wong, M.C., et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep, 2017. 7: p. 45846.
[6] Tang, L.S.Y., et al. Chronic Hepatitis B Infection: A Review. JAMA, 2018. 319(17): p. 1802-1813.
[7] Lin, M.V., L.Y. King, and R.T. Chung. Hepatitis C virus-associated cancer. Annu Rev Pathol, 2015. 10: p. 345-70.
[8] Turati, F., et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol, 2014. 25(8): p. 1526-35.
[9] Larsson, S.C. and A. Wolk. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer, 2007. 97(7): p. 1005-8.
[10] Petrick, J.L., et al. Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis. Am J Gastroenterol, 2018. 113(10): p. 1494-1505.
[11] Liu, Y., et al. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer, 2012. 48(14): p. 2125-36.
[12] Yang, W.S., et al. Diet and liver cancer risk: a narrative review of epidemiological evidence. Br J Nutr, 2020. 124(3): p. 330-340.
[13] Gerischer, L.M., et al. Acute porphyrias - A neurological perspective. Brain Behav, 2021. 11(11): p. e2389.
[14] Tan, D.J.H., et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver dis-ease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology, 2022. 23(4): p. 521-530.
[15] Xu, X.L., et al. Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis. Radiology, 2018. 287(2): p. 461-472.
[16] Fontanellas, A., et al. Current and innovative emerging therapies for porphyrias with hepatic involvement. J Hepatol, 2019. 71(2): p. 422-433.
[17] Lissing, M., et al. Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals. J Intern Med, 2022. 291(6): p. 824-836.
[18] Baravelli, C.M., et al. Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study. Orphanet J Rare Dis, 2019. 14(1): p. 77.
[19] Sardh, E., et al. High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria. J Inherit Metab Dis, 2013. 36(6): p. 1063-71.
[20] Martha S. Linet, G.G., Olof Nyren,Lene Mellemkjaer, Jorgen H. Olsen, Shannon Keehn, HansOlov Adami, and Joseph F. Fraumeni, Jr. Primary Liver Cancer, Other Malignancies, and Mortality Risks following Porphyria: A Cohort Study in Denmark and Sweden. 1999.
[21] Christophe Andant, H.P., Catherine Bogard’, Jean Faivre2, Jean-Claude Soul& Yves Nordmann’ and Jean-Charles Deybach’, Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors 2000.
[22] Seth, A.K., et al. Liver transplantation for porphyria: who, when, and how? Liver Transpl, 2007. 13(9): p. 1219-27.